This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.
In October 2017, we changed a footnote to update the information on UK marketing authorisations for entecavir.
This guideline incorporates NICE technology appraisal guidance 153, 154, 173 and recommendation 1.1 of NICE technology appraisal guidance 96. These appraisals are still mandatory for the NHS in England.
This guideline includes recommendations on:
- assessment and referral in primary care
- assessment of liver disease in secondary specialist care
- antiviral treatment
- surveillance testing for hepatocellular carcinoma in adults
Who is it for?
- Healthcare professionals
- Commissioners and providers
- People with chronic hepatitis B and their families and carers
Is this guideline up to date?
We checked this guideline in October 2017. We found no new evidence that affects the recommendations in this guideline.
Guideline development process
This guideline was previously called hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young people and adults.
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.